Thermo Fisher to sell microbiology business to PE firm Astorg for over $1 billion
TMO
Published on 04/27/2026 at 08:34 am EDT - Modified on 04/27/2026 at 08:35 am EDT
April 27 (Reuters) - Medical equipment maker Thermo Fisher Scientific said on Monday it would sell its microbiology business to private equity firm Astorg for about $1.08 billion.
o Deal consists of cash and a $50 million seller note.
o The microbiology business supplies antimicrobial susceptibility testing and culture media products used for clinical, pharmaceutical and food safety applications.
o The unit, a part of Thermo Fisher's specialty diagnostics segment, recorded $645 million in revenue in 2025.
o "The transaction reflects our active management of the company and provides additional capital we can deploy to create shareholder value," said Marc Casper, chief executive officer of Thermo Fisher.
o The company expects the transaction to close in the second half of 2026.
o Thermo Fisher expects the deal to be dilutive to adjusted earnings per share by $0.15 in the first full year after it closes.
o The company said it would provide details on the expected impact to its 2026 forecast during its second quarter earnings call.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)